Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy Dimitrios C Ziogas,1 Frosso Kostantinou,1 Evangelos Cholongitas,1 Amalia Anastasopoulou,1 Panagiotis Diamantopoulos,1 John Haanen,2 Helen Gogas1

Maria Tampaki, Nikolaos K. Gatselis, Spyridon Savvanis, Emmanouil Koullias, Asterios Saitis, Stella Gabeta, Melanie Deutsch, Emmanouil Manesis, Georgios N. Dalekos and John Koskinas

Maria Tampaki, Evangelos Ionas, Emilia Hadziyannis , Melanie Deutsch , Katerina Malagari and John Koskinas

Emilia Hadziyannis and Stephanos Hadziyannis

George N. Dalekos, Nikolaos K. Gatselis, Kalliopi Zachou, George K. Koukoulis

Adonis A. Protopapas, Theodora Mylopoulou, Vasileios P. Papadopoulos, Kiriaki Vogiatzi, Ioannis Goulis, Konstantinos Mimidis

Hariklia Kranidioti | Spilios Manolakopoulos | George Kontos| Michael S. Breen | Anastasia Kourikou | Melanie Deutsch| Maria Ester Quesada-Del-Bosque | Rocio T. Martinez-Nunez | Mohammed M. Naiyer | Christopher H. Woelk | Tilman Sanchez-Elsner| Emilia Hadziyannis | George Papatheodoridis | Salim I. Khakoo

George N. Dalekos, Nikolaos K. Gatselis,Kalliopi Zachou, George K. Koukoulis

Patients usually receive a diagnosis of primary biliary cholangitis (PBC) at an early stage, based on biochemical analyses. We investigated the proportion of patients who progress to moderate or advanced PBC and factors associated with progression and patient survival.

George N. Dalekos, John Koskinas, George V. Papatheodoridis Institute of Internal Medicine and Hepatology, Larissa; University Hospital of Larissa; National and Kapodistrian University of Athens, “Hippokratio” General Hospital of Athens, Athens; Medical School of National and Kapodistrian University of Athens, “Laiko” General Hospital of Athens, Athens, Greece